THELMA Therapeutics Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 2,212.6 million compared to KRW 2,092.84 million a year ago. Net loss was KRW 1,414.46 million compared to KRW 4,625.59 million a year ago. Basic loss per share from continuing operations was KRW 58 compared to KRW 346 a year ago. Basic loss per share was KRW 58 compared to KRW 346 a year ago.
For the six months, sales was KRW 4,233.65 million compared to KRW 4,309.65 million a year ago. Net loss was KRW 2,751.11 million compared to KRW 6,947.61 million a year ago. Basic loss per share from continuing operations was KRW 112 compared to KRW 535 a year ago. Basic loss per share was KRW 112 compared to KRW 535 a year ago.